Malignancies in the rheumatoid arthritis abatacept clinical development programme: An epidemiological assessment

Annals of the Rheumatic Diseases

Volumn 68, Issue 12, 2009, Pages 1819-1826

  Simon, T A ^a   Smitten, A L ^a   Franklin, J ^b   Askling, J ^c   Lacaille, D ^d   Wolfe, F ^e   Hochberg, M C ^f   Qi, K ^a   Suissa, S ^g  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF KANSAS   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DATA BASE; FEMALE; HEALTH PROGRAM; HUMAN; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGE DISTRIBUTION; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EPIDEMIOLOGIC METHODS; EUROPE; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEOPLASMS; NORTH AMERICA; RESEARCH DESIGN; YOUNG ADULT;

EID: 72249096209     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.097527     Document Type: Article

References (45)

1. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993;177:165-173 (Pubitemid 23008096)
2. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-1915 (Pubitemid 37409707)
3. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-876 (Pubitemid 46768126)
4. Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084-1089
5. Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective costimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy. Ann Rheum Dis 2008;67:547-554
6. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-2285
7. Food and Drug Administration. Guidance for industry. Premarketing risk assessment. http://www.fda.gov/CDER/guidance/6357fnl.htm (accessed 27 Dec 2006).
8. Smitten AL, Simon TA, Hochberg MC, et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis Arthritis Res Ther 2008;10:R45.
9. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-2271 (Pubitemid 41117408)
10. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007;66:228-234 (Pubitemid 46226059)
11. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-1123 (Pubitemid 41317434)
12. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807-2816 (Pubitemid 44497759)
13. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-1103
14. Schiff M, Pritchard C, Zhou X, et al. The efficacy of abatacept in patients with active rheumatoid arthritis and an inadequate response to anti-TNF Therapy: the ARRIVE Trial. Arthritis Rheum 2007;56(suppl 9):S391; Abstract 942.
15. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-1439 (Pubitemid 46764070)
16. Lacaille D, Anis AH, Guh DP, et al. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 2005;53:241-248 (Pubitemid 40530165)
17. Symmons DP, Silman AJ. The Norfolk Arthritis Register (NOAR). Clin Exp Rheumatol 2003;21(5 suppl 31):S94-9.
18. Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-712 (Pubitemid 43799167)
19. Lawson DH, Sherman V, Hollowell J. The General Practice Research Database. Scientific and Ethical Advisory Group. QJM 1998;91:445-452
20. National Cancer Institute. Surveillance, epidemiology and end results. http://seer. cancer.gov (accessed Dec 2008).
21. Abásolo L, Júdez E, Descalzo MA, et al, EMECAR Study Group. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a south European population. Semin Arthritis Rheum 2008;37:388-397
22. Franklin J, Lunt M, Bunn D, et al. Influence of inflammatory polyarthritis on cancer incidence and survival. Arthritis Rheum 2007;56:790-798
23. Matteson EL, Hickey AR, Maguire L, et al, Members of the Rheumatoid Arthritis Azathioprine Registry Steering Committee. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. J Rheumatol 1991;18:809-814
24. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 2007;56:2886-2895
25. Thomas E, Brewster DH, Black RJ, et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502. (Pubitemid 30747077)
26. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-1426 (Pubitemid 41623851)
27. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997;40:1580-1586
28. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-311 (Pubitemid 23068804)
29. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-1757
30. Moritomo H, Ueda T, Hiyama T, et al. The risk of cancer in rheumatoid arthritis patients in Japan. Scand J Rheumatol 1995;24:157-159
31. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor a antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2757-2764 (Pubitemid 44497754)
32. Kauppi M, Pukkala E, Isomaki H. Low incidence of colorectal cancer in patients with rheumatoid arthritis. Clin Exp Rheumatol 1996;14:551-553 (Pubitemid 26335479)
33. Kauppi M, Pukkala E, Isomaki H. Excess risk of lung cancer in patients with rheumatoid arthritis. J Rheumatol 1996;23:1484-1485
34. McKendry RJR, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993;20:1850-1856 (Pubitemid 24031586)
35. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-1420 (Pubitemid 41623850)
36. Ekstrom K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003;48:963-970 (Pubitemid 36418238)
37. Franklin J, Lunt M, Bunn D, et al. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 2006;65:617-622
38. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699-703. (Pubitemid 40559295)
39. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188
40. Chakravarty EF, Genovese MC. Associations between rheumatoid arthritis and malignancy. Rheum Dis Clin North Am 2004;30:271-284
41. Silman AJ, Petrie J, Hazleman B, et al. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988;47:988-992 (Pubitemid 19005407)
42. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
43. Georgescu L, Quinn GC, Schwartzman S, et al. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997;26:794-804. (Pubitemid 27274443)
44. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909-3915 (Pubitemid 35332027)
45. Food and Drug Administration. Guidance for industry. Good pharmacovigilance practices and pharmacoepidemiologic assessment. http://www.fda.gov/cber/gdlns/ pharmacovig.htm (accessed 11 Jan 2007).